Want to join the conversation?
Going forward, $V said that reported international revenue growth will depend on the interplay between volume growth and the currency translation drag. Other revenues were down 3% hurt by lower license fees generated outside the US due to slowing payments volume. Incentives were in line with expectations at the midpoint of the guidance range.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.